A Multiple-dose, Steady-state, Double-blind, Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Mild to Moderate Alzheimer's Disease ("MAD Study")
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Lithium (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- Acronyms MAD study
- Sponsors Alzamend Neuro
- 02 Oct 2023 According to an Alzamend Neuro media release, on the favorable AL001 safety profile observed and extensive safety data on the drug's constituent components, the AL001 development program may qualify for a Section 505(b)(2) New Drug Application ("NDA") pathway for FDA approval, which is available to new formulations of an approved drug.
- 19 Jul 2023 Status changed from active, no longer recruiting to completed.
- 22 Jun 2023 Positive result presented in the Alzamend Neuro Media Release.